Interestingly, CML CD26+ cells have been selectively targeted in vitro using an immunoliposome system loaded with venetoclax, showing that these proteins can also be used to therapeutically target subpopulations of leukaemic cells [52]. This evidence concerns the gene DPP4 and chronic myelogenous leukemia, BCR-ABL1 positive.